5.7 Fuchs' Endothelial Corneal Dystrophy

Date of revision:

10/04/2026

Date of next review:

10/04/2028 

Date of publication:

20/04/2026


Differential diagnosis (1)

  • Pseudophakic/aphakic bullous keratopathy

  • Posterior polymorphous dystrophy

  • Congenital hereditary endothelial dystrophy

  • Primary central corneal guttata (may not be progressive)

  • Other causes of endothelial decompensation

  • Corneal hydrops in keratoconus

  • Keratic Precipitates (KP) in anterior uveitis

  • Pigment dispersion syndrome

  • Herpetic stromal keratitis

  • Interstitial keratitis

  • Recurrent corneal erosion

  • Contact lens overwear


Possible management by optometrist

Advice (1)

  • Use photography and imaging (including specular microscopy and Scheimpflug tomography, where available) to document endothelial changes

  • Measure central corneal thickness (CCT) to monitor disease progression

  • For painful epithelial bullae, consider a therapeutic contact lens to reduce friction and protect exposed nerves

  • Recommend sunglasses or tinted lenses for patients troubled by glare

  • Ensure Fuchs’ Endothelial Corneal Dystrophy (FECD) is clearly documented before cataract referral

Treatment

  • Ocular lubricants for symptomatic relief as required (drops/gel for use during the day ± unmedicated ointment for use at bedtime)(1). Refer to local formularies for suitable options (6)

  • Hyperosmotic agents (e.g. sodium chloride 5%) may be tried in moderate to severe cases, although trials do not support meaningful symptom improvement (1)

 


Typical adult dosage/duration

(Blue text = IP, black text = non-IP)

  • As required (see ‘Treatment’ above)

Regimens should be adjusted according to severity and patient factors (e.g. age, weight, pregnancy, renal function). Prescribing should follow local formulary and national guidance where available (7).

In cases of known sensitivities, please consult local formularies for alternative options (7).


Further management options (1)

  • Initial management with possible routine referral


Possible management in secondary care or local/community pathways where available (1)

Diagnostic Support

  • Confirmation of FECD diagnosis

  • Imaging, specular microscopy and endothelial cell counts

  • Measurement of CCT and repeat assessments to monitor change over time

Cataract Co-Management

  • Patients with early FECD require careful counselling prior to cataract surgery, as uncomplicated procedures may still risk postoperative decompensation

  • Endothelial cell counts may aid prognosis

Surgical Options (for symptomatic progression or decompensation)

When conservative measures fail, the following procedures may be offered:

  • Endothelial keratoplasty (EK - preferred modern treatment):

    • Descemet’s Stripping Automated Endothelial Keratoplasty (DSAEK)

    • Descemet’s Stripping Endothelial Keratoplasty (DSEK)

    • Ultrathin Descemet’s Stripping Endothelial Keratoplasty (UT-DSEK)

    • Descemet’s Membrane Endothelial Keratoplasty (DMEK)

  • Penetrating keratoplasty (PK) – now less common, largely superseded by EK techniques

  • Procedures may be combined with cataract surgery when indicated

  • Evidence (low certainty) suggests DMEK offers faster visual recovery and superior outcomes compared with DSEK


College of Optometrists Clinical Management Guideline (1) 

Fuchs endothelial corneal dystrophy (FECD) - College of Optometrists

* With special thanks to The College of Optometrists for providing the evidence framework for diagnosis and management from the Clinical Management Guidelines (CMGs) for this condition. All references to the College/CMGs are included where appropriate and form the basis of the Community Eyecare Guidelines.


Guidance is informed by the following sources 

  1. College of Optometrists Clinical Management Guidelines Clinical Management Guidelines - College of Optometrists

  2. Advisory alignment with the College of Optometrists Formulary Optometrists' Formulary - College of Optometrists

  3. Advisory alignment with the BNF BNF (British National Formulary) | NICE

  4. Advisory alignment with the Summary Product Characteristics taken from the EMC Home - electronic medicines compendium (emc)

  5. Advisory alignment with Scottish Health Board formularies (where a clear majority is present) *

  6. Advisory alignment with expert consensus (CEGG), informed by sources 2-5 above

  7. Advisory alignment with expert consensus (CEGG) 

  8. “Annex C of the Statement” https://www.eyes.nhs.scot/for-professionals/legislation/

* Scottish formularies should be available within the Prescribing section of your Health Board pages on the eyes.nhs.scot website. If unavailable, contact your local Health Board for further information; Health Boards landing page 

 


If you have a query relating to this page, please email NSS.ComEyecareGuidelineGroup@nhs.scot